Tony Badrick , Jason Tseung , Maddison Frogley , Sze Yee Chai , Brett A. Lidbury
{"title":"Development of an external quality assurance (EQA) structure to evaluate the quality of genetic pathology reporting","authors":"Tony Badrick , Jason Tseung , Maddison Frogley , Sze Yee Chai , Brett A. Lidbury","doi":"10.1016/j.cca.2025.120263","DOIUrl":null,"url":null,"abstract":"<div><div>A standard for reporting genetic pathology results currently does not exist as a consensus. While effective reports are produced, there is lack of consistency on which details to present or to emphasise, and the ultimate report often reflects an individual practitioner’s preferences derived from anecdotal experience. Genetic knowledge is complex, so poor and/or inconsistent reporting could make the application of pathology results to patient management more challenging than necessary. The aim of this study was to combine expert knowledge with machine learning (ML) applications to design a template to encourage consistent and accurate genetic reporting. To investigate genetic reporting quality within Australasia, past melanoma genetics reports produced in response to RCPA Quality Assurance Program (RCPAQAP) audits were compiled for retrospective text analyses to determine word frequencies and patterns. These text pattern analyses were supported by an investigation of reporting criteria consistency for solid tumours, as well as a narrative review of the broader literature, by a genetic pathology expert to contextualise these results, with the ultimate results combined into a suggested template. These results will be augmented via further ML studies on report structure.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"572 ","pages":"Article 120263"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A standard for reporting genetic pathology results currently does not exist as a consensus. While effective reports are produced, there is lack of consistency on which details to present or to emphasise, and the ultimate report often reflects an individual practitioner’s preferences derived from anecdotal experience. Genetic knowledge is complex, so poor and/or inconsistent reporting could make the application of pathology results to patient management more challenging than necessary. The aim of this study was to combine expert knowledge with machine learning (ML) applications to design a template to encourage consistent and accurate genetic reporting. To investigate genetic reporting quality within Australasia, past melanoma genetics reports produced in response to RCPA Quality Assurance Program (RCPAQAP) audits were compiled for retrospective text analyses to determine word frequencies and patterns. These text pattern analyses were supported by an investigation of reporting criteria consistency for solid tumours, as well as a narrative review of the broader literature, by a genetic pathology expert to contextualise these results, with the ultimate results combined into a suggested template. These results will be augmented via further ML studies on report structure.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.